The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2022Alpha-synuclein Aggregation in the Brainstem: Developing a Model and Discovering a New Biomarker for Parkinson Disease
Study Rationale: Abnormal accumulation of alpha-synuclein (a neuronal protein) in distinct regions of the brain is a well known feature in Parkinson’s disease (PD). A sizeable number of people with PD...
-
Proof-of-Concept Testing of PD Therapeutics, 2022Using Data from the LEAPS Project to Improve the Accuracy of Assays that Measure Alpha-synuclein
Study Rationale: The scientific and clinical research community working on Parkinson’s disease (PD) is in need of biomarkers to facilitate the monitoring of disease progression and efficacy of...
-
Proof-of-Concept Testing of PD Therapeutics, 2022Therapeutic Targeting of Mitochondrial Biogenesis to Address Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a complex disorder involving the degeneration of specific brain cells that lead to severe impairments in movement and cognition. Although the exact cause...
-
Target Advancement Program, 2022Enhancing N-glycosylation of Glucocerebrosidase and other Lysosomal Enzymes as a Disease Modifying Therapy for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is an age-related neurological movement disorder characterized by the abnormal aggregation of a protein called α-synuclein (α-syn) in the brain. Normally...
-
Target Advancement Program, 2022Assessing the Ability of Neuronal Modulators to Treat or Modify the Motor Symptoms of Parkinson’s Disease
Study Rationale: The dopamine-producing cells that are lost in Parkinson’s disease (PD) express a unique type of cell-surface protein called the M5 muscarinic acetylcholine receptor. The presence of...
-
Target Advancement Program, 2022Development of an Antibody for Isolating Mitochondria from Preclinical Models and Individuals with Parkinson’s Disease
Study Rationale: Previous research has demonstrated that mitochondria — the energy-generating centers in the cell — are impaired in the brains of people with Parkinson’s disease (PD). However, the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.